NCT02422290

Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: New York State Psychiatric Institute · Academic / Other
• Sex: All
• Age: 14 Years – 22 Years
• Healthy volunteers: Not accepted

Summary

This pilot study is proposed to determine the acceptability, feasibility and potential efficacy of ketamine, a medication that modulates glutamate in the brain, as a rapid treatment for obsessive-compulsive disorder (OCD) symptoms in adolescents and young adults with OCD. This study will recruit 6 youth (ages 14-22) who are diagnosed with clinically significant OCD and have failed at least one adequate trial of a Serotonin Reuptake Inhibitor (SRI) medication and a course of Cognitive-Behavioral Therapy (CBT) (unless unable to access or tolerate) for OCD in the past. Participants will receive a single infusion of intravenous ketamine and be assessed at regular intervals post-infusion for up to 14 days. At the end of the 14-day treatment phase, all participants will be offered three months of open treatment for OCD with medication and/or CBT.

Detailed description

See Brief Summary for description.

Conditions

• Obsessive-Compulsive Disorder

Interventions

Type	Name	Description
DRUG	Ketamine	Single infusion of IV Ketamine, 0.5mg/kg

Timeline

• Start date: 2015-03-01
• Primary completion: 2018-02-21
• Completion: 2020-07-31
• First posted: 2015-04-21
• Last updated: 2020-08-17
• Results posted: 2020-08-17

Locations

1 site across 1 country: United States